4//SEC Filing
King Andrew James 4
Accession 0001209191-23-023351
CIK 0001435049other
Filed
Apr 4, 8:00 PM ET
Accepted
Apr 5, 4:43 PM ET
Size
9.5 KB
Accession
0001209191-23-023351
Insider Transaction Report
Form 4
King Andrew James
Head of Renal Discovery
Transactions
- Exercise/Conversion
Stock Option (right to buy)
2023-04-03−2,500→ 43,047 totalExercise: $0.35Exp: 2029-06-05→ Common Stock (2,500 underlying) - Exercise/Conversion
Common Stock
2023-04-03$0.35/sh+2,500$875→ 21,992 total - Sale
Common Stock
2023-04-03$23.34/sh−5,000$116,718→ 16,992 total
Footnotes (3)
- [F1]The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 2, 2022
- [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.98 to $23.67, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.
- [F3]The stock option vested as to 25% of the total shares on May 6, 2020, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on the vesting date.
Documents
Issuer
CHINOOK THERAPEUTICS, INC.
CIK 0001435049
Entity typeother
Related Parties
1- filerCIK 0001823187
Filing Metadata
- Form type
- 4
- Filed
- Apr 4, 8:00 PM ET
- Accepted
- Apr 5, 4:43 PM ET
- Size
- 9.5 KB